Dynavax Technologies (NASDAQ:DVAX) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a buy rating to a hold rating in a research note released on Tuesday.

DVAX has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group decreased their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a research report on Thursday, April 17th. Finally, William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st.

Dynavax Technologies Stock Performance

Shares of DVAX stock opened at $10.93 on Tuesday. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The company has a market cap of $1.34 billion, a PE ratio of 60.74 and a beta of 1.26. The company’s fifty day simple moving average is $12.49 and its 200-day simple moving average is $12.59. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting analysts’ consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $72.03 million for the quarter, compared to analysts’ expectations of $72.70 million. As a group, equities research analysts anticipate that Dynavax Technologies will post 0.32 EPS for the current year.

Institutional Trading of Dynavax Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Deep Track Capital LP increased its holdings in Dynavax Technologies by 42.0% in the fourth quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company’s stock valued at $227,197,000 after buying an additional 5,265,000 shares during the last quarter. Deerfield Management Company L.P. Series C increased its holdings in shares of Dynavax Technologies by 23,990.1% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company’s stock valued at $66,325,000 after acquiring an additional 5,172,263 shares during the last quarter. Norges Bank bought a new stake in Dynavax Technologies during the fourth quarter valued at $7,762,000. D. E. Shaw & Co. Inc. raised its holdings in shares of Dynavax Technologies by 34.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company’s stock worth $24,497,000 after purchasing an additional 486,981 shares during the period. Finally, WINTON GROUP Ltd lifted its position in shares of Dynavax Technologies by 339.0% in the 4th quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company’s stock worth $5,450,000 after buying an additional 329,579 shares during the last quarter. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.